Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up ...

Januvia (sitagliptin) is a medication for type 2 diabetes. Along with diet and exercise, it can help lower blood sugar levels. Medicare Part D will generally cover prescription drugs, like Januvia.

Januvia (sitagliptin) is a medication for type 2 diabetes. Along with diet and exercise, it can help lower blood sugar levels. Medicare Part D will generally cover prescription drugs, like Januvia.

Answer • Sitagliptin (Januvia) is an oral medication for diabetes mellitus. The way it works is complicated: It inhibits a molecule called “DPP-4,” which causes an increase in another ...

The fact is, it’s still early in the game for Afrezza and truth be told we really won’t know how the drug is doing for another few quarters.

Merck & Co Inc <MRK.N> will soon be using a bio-engineered enzyme to make its diabetes drug Januvia in a greener approach to drug manufacturing that both improves yield and cuts cost, researchers ...

Januvia was the first to market and is the top selling drug in its class of drugs, called DPP-4 inhibitors. But they’re not as broadly as effective as the class of drugs that Bydureon and ITCA ...

The base study looked at 412 patients over a year and then included them in an all-patients-treated analysis of efficacy over the next year. Januvia combined with metformin were found to control ...